Back to Search Start Over

Vector replication and expression of HIV-1 antigens by the HIV/AIDS vaccine candidate MVA-B is not affected by HIV-1 protease inhibitors

Authors :
García-Arriaza, Juan
Arnáez, Pilar
Jiménez, José Luis
Gómez, Carmen E.
Muñoz-Fernández, María Ángeles
Esteban, Mariano
Source :
Virus Research. Aug2012, Vol. 167 Issue 2, p391-396. 6p.
Publication Year :
2012

Abstract

Abstract: MVA-B is an attenuated poxvirus vector expressing human immunodeficiency virus type 1 Env, Gag, Pol, and Nef antigens from clade B, and is considered a promising HIV/AIDS vaccine candidate. Recently, a phase I clinical trial in human healthy volunteers has shown that MVA-B is safe and highly immunogenic, inducing broad, polyfunctional, and long-lasting CD4+ and CD8+ T cell responses to HIV-1 antigens, with preference for effector memory T cells; and it also triggers the induction of specific antibodies to Env in most of the vaccines. While MVA recombinants expressing HIV-1 antigens are being used or plan to use in therapeutic clinical trials, little is known on the effect of HIV-1 highly active antiretroviral therapy in MVA life cycle. To define this role, here we have evaluated in established cell cultures and human dendritic cells to what extent different HIV-1 protease inhibitors affect virus replication and expression of HIV-1 antigens during MVA-B infection. The results obtained revealed that the most commonly used HIV-1 protease inhibitors (atazanavir, ritonavir, and lopinavir) had no effect on MVA-B virus growth kinetics, even at higher concentrations than those normally used on HAART. Furthermore, expression of gp120 and the fused Gag-Pol-Nef polyprotein in permissive and non-permissive cells infected with MVA-B were also not affected. These findings are relevant information for the therapeutic use of MVA-B as an HIV-1/AIDS vaccine. [Copyright &y& Elsevier]

Details

Language :
English
ISSN :
01681702
Volume :
167
Issue :
2
Database :
Academic Search Index
Journal :
Virus Research
Publication Type :
Academic Journal
Accession number :
77730657
Full Text :
https://doi.org/10.1016/j.virusres.2012.05.020